Aaron E. Miller

Last updated

Aaron E. Miller is an American neurologist, the first Chairman of the Multiple Sclerosis section of the American Academy of Neurology (AAN) and recognized as a multiple sclerosis clinician. [1] [2]

Contents

Miller is both a professor of neurology at the Icahn School of Medicine at Mount Sinai and medical director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, both part of the Mount Sinai Medical Center. Additionally, he continues to serve as co-director of the Multiple Sclerosis Care Center at Maimonides Medical Center in Brooklyn. [3]

Biography

Miller graduated from Brandeis University with honors in 1964 and received his medical degree from New York University School of Medicine in 1968. He completed his residency at the Albert Einstein College of Medicine, later acquiring additional postdoctoral training in neurovirology and immunology at the Johns Hopkins School of Hygiene and Public Health.

He was a Lieutenant Commander in the United States Navy from 1971 to 1973.

From 1981 until 2004, Miller headed the Division of Neurology at Brooklyn's Maimonides Medical Center; he continues to serve as co-director of its Multiple Sclerosis Care Center.

In 2004, he assumed his current title of medical director of the CGD Center for MS at Mount Sinai Hospital, of which Fred D. Lublin, MD is Director.[ citation needed ] Miller currently serves as Editor of Continuum, AAN's bimonthly continuing education publication, and he is a reviewer for many prominent journals including the New England Journal of Medicine , Neurology and the Archives of Neurology as well as co-author of one of the most-frequently cited articles in Brain: A Journal of Neurology. [4] [5] [6] [7]

In 2001, Miller became the Chief Medical Officer and Chairman of the Clinical Advisory Board of the National Multiple Sclerosis Society (NMSS); he served as chairman of the Clinical Advisory Committee of the New York chapter of the NMSS from 1991 to 2004 [8] and has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis, and Teva Neuroscience.

He is listed in New York magazine's "Best Doctors" issue of 2008. [9]

Awards

Memberships and affiliations

Publications

Partial list:

Related Research Articles

<span class="mw-page-title-main">Multiple sclerosis</span> Disease that damages the myelin sheaths around nerves

Multiple sclerosis (MS) is an autoimmune disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, vision loss, eye pain, muscle weakness, and loss of sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks or building up over time. In the relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances. In the progressive forms of MS, bodily function slowly deteriorates and disability worsens once symptoms manifest and will steadily continue to do so if the disease is left untreated.

<span class="mw-page-title-main">Interferon beta-1a</span> Cytokine in the interferon family

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.

Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. Closely related is interferon beta 1a, also indicated for MS, with a very similar drug profile.

<span class="mw-page-title-main">McDonald criteria</span>

The McDonald criteria are diagnostic criteria for multiple sclerosis (MS). These criteria are named after neurologist W. Ian McDonald who directed an international panel in association with the National Multiple Sclerosis Society (NMSS) of America and recommended revised diagnostic criteria for MS in April 2001. These new criteria intended to replace the Poser criteria and the older Schumacher criteria. They have undergone revisions in 2005, 2010 and 2017.

The National Multiple Sclerosis Society (NMSS) is a nonprofit organization founded in 1946.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

<span class="mw-page-title-main">Glatiramer acetate</span> Medication

Glatiramer acetate, sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis. Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.

Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process. IDDs share characteristics with and are often grouped together under Multiple Sclerosis. They are sometimes considered different diseases from Multiple Sclerosis, but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course.

<span class="mw-page-title-main">Multiple sclerosis signs and symptoms</span>

Multiple sclerosis can cause a variety of symptoms: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; problems in speech (dysarthria) or swallowing (dysphagia), visual problems, fatigue and acute or chronic pain syndromes, bladder and bowel difficulties, cognitive impairment, or emotional symptomatology. The main clinical measure in progression of the disability and severity of the symptoms is the Expanded Disability Status Scale or EDSS.

<span class="mw-page-title-main">Laquinimod</span> Chemical compound

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.

Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.

<span class="mw-page-title-main">Tumefactive multiple sclerosis</span> Medical condition

Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). It is called tumefactive as the lesions are "tumor-like" and they mimic tumors clinically, radiologically and sometimes pathologically.

<span class="mw-page-title-main">Corinne Goldsmith Dickinson Center for Multiple Sclerosis</span>

The Corinne Goldsmith Dickinson Center for Multiple Sclerosis is a multiple sclerosis research and treatment center in New York City.

Fred D. Lublin is an American neurologist and an authority on the treatment of multiple sclerosis. Along with colleagues at the National Multiple Sclerosis Society, his work redefined the clinical course definitions of MS.

<span class="mw-page-title-main">Stephen L. Hauser</span> American physician

Stephen L. Hauser is a professor of the Department of Neurology at the University of California, San Francisco (UCSF) specializing in immune mechanisms and multiple sclerosis (MS). He has contributed to the establishment of consortia that have identified more than 50 gene variants that contribute to MS risk.

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market.

Rhonda Renee Voskuhl is an American physician, research scientist, and professor. She is a member of the Brain Research Institute (BRI) at the David Geffen School of Medicine at UCLA and is the director of its Multiple Sclerosis Program. Voskuhl has published numerous scientific articles in academic journals and has served in the role of principal investigator for several treatment trials investigating potential treatments for multiple sclerosis (MS).

Pasquale Calabrese born 27 February 1961 in Naples, Italy, is an Italian professor of clinical neurosciences at the University of Basel, Faculty of Psychology, Department of Molecular and Cognitive Neurosciences. He is a neuroscientist, experimental neurologist and medical neuropsychologist.

Anti-AQP4 diseases, are a group of diseases characterized by auto-antibodies against aquaporin 4.

Brenda Banwell is Chief of the Division of Neurology and Co-Director of the Neuroscience Center, and Professor of Neurology at Children's Hospital of Philadelphia and holder of the Grace R. Loeb Endowed Chair in Neurosciences. She also holds the title of Professor of Pediatrics and Neurology at the Perelman School of Medicine at the University of Pennsylvania.

References

  1. ↑ "Corinne Goldsmith Dickinson Center for Multiple Sclerosis". Archived from the original on 2009-04-09. Retrieved 2008-12-10.
  2. ↑ "Aaron Miller - Neurology | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2023-02-22.
  3. ↑ Baltimore City College Alumni Association Archived August 28, 2008, at the Wayback Machine
  4. ↑ Continuum Editorial Board Archived December 7, 2008, at the Wayback Machine
  5. ↑ New England Journal of Medicine
  6. ↑ American Medical Association
  7. ↑ Brain Archived February 6, 2010, at the Wayback Machine
  8. ↑ MediciNova Archived November 19, 2008, at the Wayback Machine
  9. ↑ New York Magazine: Best Doctors, Aaron E. Miller
  10. ↑ New York Academy of Medicine Archived October 31, 2008, at the Wayback Machine
  11. ↑ National MS Society Archived June 13, 2010, at the Wayback Machine
  12. ↑ American Academy of Neurology
  13. ↑ "Scientific Advisory Committee Member Listing 2022-2023" (PDF). National MS Society. October 1, 2022. Retrieved 22 February 2023.
  14. ↑ "Committee Roster 2023-24" (PDF). International Advisory Committee on Clinical Trials in Multiple Sclerosis. Retrieved 22 February 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.